Clinical trial
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors
NCT03514121 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 27, 2018
- Completion date
- April 21, 2021
- Enrollment
- 95 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors, breast cancer, endometrial cancer, ovarian cancer